» Articles » PMID: 30404557

Multivalent Activation of GLP-1 and Sulfonylurea Receptors Modulates β-cell Second-messenger Signaling and Insulin Secretion

Overview
Specialties Cell Biology
Physiology
Date 2018 Nov 9
PMID 30404557
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Linking two pharmacophores that bind different cell surface receptors into a single molecule can enhance cell-targeting specificity to cells that express the complementary receptor pair. In this report, we developed and tested a synthetic multivalent ligand consisting of glucagon-like peptide-1 (GLP-1) linked to glibenclamide (Glb) (GLP-1/Glb) for signaling efficacy in β-cells. Expression of receptors for these ligands, as a combination, is relatively specific to the β-cell in the pancreas. The multivalent GLP-1/Glb increased both intracellular cAMP and Ca, although Ca responses were significantly depressed compared with the monomeric Glb. Moreover, GLP-1/Glb increased glucose-stimulated insulin secretion in a dose-dependent manner. However, unlike the combined monomers, GLP-1/Glb did not augment insulin secretion at nonstimulatory glucose concentrations in INS 832/13 β-cells or human islets of Langerhans. These data suggest that linking two binding elements, such as GLP-1 and Glb, into a single bivalent ligand can provide a unique functional agent targeted to β-cells.

Citing Articles

Effect of Type-2 Diabetes Mellitus on the Expression and Function of Smooth Muscle ATP-Sensitive Potassium Channels in Human Internal Mammary Artery Grafts.

Rajkovic J, Peric M, Stanisic J, Gostimirovic M, Novakovic R, Djokic V Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065708 PMC: 11280115. DOI: 10.3390/ph17070857.


Insulinoma-derived pseudo-islets for diabetes research.

Hart N, Weber C, Price N, Banuelos A, Schultz M, Huey B Am J Physiol Cell Physiol. 2021; 321(2):C247-C256.

PMID: 34106785 PMC: 8424674. DOI: 10.1152/ajpcell.00466.2020.

References
1.
Caplan M, Rosca E . Targeting drugs to combinations of receptors: a modeling analysis of potential specificity. Ann Biomed Eng. 2005; 33(8):1113-24. DOI: 10.1007/s10439-005-5779-1. View

2.
Lizio M, Harshbarger J, Shimoji H, Severin J, Kasukawa T, Sahin S . Gateways to the FANTOM5 promoter level mammalian expression atlas. Genome Biol. 2015; 16:22. PMC: 4310165. DOI: 10.1186/s13059-014-0560-6. View

3.
Portoghese P, LARSON D, Sayre L, Yim C, Ronsisvalle G, Tam S . Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. J Med Chem. 1986; 29(10):1855-61. DOI: 10.1021/jm00160a010. View

4.
Nolan C, Damm P, Prentki M . Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011; 378(9786):169-81. DOI: 10.1016/S0140-6736(11)60614-4. View

5.
DeFronzo R, Ratner R, Han J, Kim D, Fineman M, Baron A . Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28(5):1092-100. DOI: 10.2337/diacare.28.5.1092. View